Keyphrases
Metformin
100%
Statins
100%
Gastrointestinal Cancer
100%
Proton Pump Inhibitors
100%
Colorectal Cancer
50%
Gastric Cancer
50%
Meta-analysis
50%
Esophageal Cancer
50%
Statin Use
50%
Type 2 Diabetes Mellitus (T2DM)
25%
Synergistic Effect
25%
Colorectal Cancer Patients
25%
Dose Effect
25%
Cancer Diagnosis
25%
Phase II Study
25%
Type 2 Diabetic Patients
25%
Chemopreventive
25%
Anticancer Effect
25%
Large Cohort
25%
Population-based Study
25%
Systemic Chemotherapy
25%
Prolonged Survival
25%
Better Prognosis
25%
Gastric Cancer Risk
25%
Nondysplastic Barrett's Esophagus
25%
Advanced Gastrointestinal Cancer
25%
Esophageal Adenocarcinoma
25%
Medicine and Dentistry
Glycon
100%
Statin
100%
Proton-Pump Inhibitor
100%
Gastrointestinal Cancer
100%
Colorectal Carcinoma
75%
Abdominal Cancer
75%
Medicine
50%
Meta-Analysis
50%
Observational Study
50%
Esophageal Cancer
50%
Cancer Diagnosis
25%
Drug Therapy
25%
Patient with Type 2 Diabetes
25%
Cancer Risk
25%
Maturity Onset Diabetes of the Young
25%
Cohort Analysis
25%
Barrett Esophagus
25%
Esophageal Adenocarcinoma
25%
Chemotherapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
100%
Metformin
100%
Digestive System Cancer
100%
Proton Pump Inhibitor
100%
Colorectal Carcinoma
75%
Abdominal Cancer
75%
Observational Study
50%
Statin (Protein)
50%
Esophagus Cancer
50%
Chemotherapy
25%
Cohort Study
25%
Barrett Esophagus
25%
Esophageal Adenocarcinoma
25%
Non Insulin Dependent Diabetes Mellitus
25%